Literature DB >> 6883314

Enhanced metastasis formation by combined hyperthermia and hyperglycemia in rats bearing Walker 256 carcinosarcoma.

S A Shah, R K Jain, P L Finney.   

Abstract

Hyperglycemia has been shown to decrease tumor pH and blood flow rates, consequently this could increase the sensitivity of tumor to hyperthermia. Combined waterbath hyperthermia (43 degrees C/2 h) and hyperglycemia (6 g/kg, i.p.) was investigated on survival of rats bearing a metastasizing form of Walker 256 carcinosarcoma. Hyperthermia alone increased the survival rate of animals from 19% to 42%. Hyperglycemia promoted more uniform tumor heating in the foot. However, combined hyperthermia and hyperglycemia led to a significant decrease in the survival rate of animals (10%; P less than 0.001), and most rats died with widespread metastasis in lymph nodes, lungs and kidneys. These findings do not support the postulate that hyperglycemia leads to sensitization of tumor destruction by hyperthermia.

Entities:  

Mesh:

Year:  1983        PMID: 6883314     DOI: 10.1016/0304-3835(83)90101-5

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  3 in total

1.  Induced hyperglycemia and tumor chemotherapy: experimental and clinical studies.

Authors:  S P Osinsky; G V Evtushenko; E A Annin; L N Bubnovskaja
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

2.  Acute changes of systemic parameters in tumour-bearing rats, and of tumour glucose, lactate, and ATP levels upon local hyperthermia and/or hyperglycaemia.

Authors:  W Krüger; W K Mayer; C Schaefer; M Stohrer; P Vaupel
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 3.  Review of the Clinical Evidences of Modulated Electro-Hyperthermia (mEHT) Method: An Update for the Practicing Oncologist.

Authors:  Attila M Szasz; Carrie Anne Minnaar; Gyongyver Szentmártoni; Gyula P Szigeti; Magdolna Dank
Journal:  Front Oncol       Date:  2019-11-01       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.